ABSTRACT
BACKGROUND: Erythropoietic effects of molidustat, a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, were previously demonstrated in healthy cats. OBJECTIVE: To evaluate the safety and erythropoietic effects of daily PO administration of molidustat in anemic cats with chronic kidney disease (CKD). ANIMALS: Twenty-one client-owned CKD cats (4-17 years old) with anemia. METHODS: Multicenter field study; randomized, masked, and placebo-controlled. Cats were treated PO once daily for 28 days with suspensions of control product (CP; n = 6) or 5 mg/kg of molidustat (n = 15). Hematocrit (HCT) was evaluated at weekly intervals. Individual cat treatment success was defined as a ≥4% point increase in HCT compared to baseline. RESULTS: Control group mean HCT remained low throughout the study (20.1%-23.4%). Mean HCT of molidustat-treated cats increased weekly, and a significant increase compared to baseline (23.6%) was first observed on Day 21 (27.3%; P < .001; 95% confidence interval [CI], 1.69-5.67). Compared to CP group, mean HCT was significantly higher on Day 21 (27.3% vs 20.1%; P < .001; 95% CI, 2.91-10.75) but not significantly higher on Day 28 (27.8% vs 23.4%; P = .06; 95% CI, -0.23 to 9.88). The number of individual treatment successes on Day 28 was higher among remaining molidustat-treated cats (7/14) compared to remaining control cats (1/5), but there was no significant difference between groups. CONCLUSIONS AND CLINICAL IMPORTANCE: Daily PO molidustat administration may stimulate a clinically relevant erythropoietic response in anemic cats with CKD. This HIF-PH inhibitor may be an alternative for managing anemia in cats compared to recombinant EPO treatment.
Subject(s)
Anemia , Cat Diseases , Prolyl-Hydroxylase Inhibitors , Pyrazoles , Renal Insufficiency, Chronic , Triazoles , Animals , Cats , Anemia/drug therapy , Anemia/etiology , Anemia/veterinary , Cat Diseases/drug therapy , Hypoxia/veterinary , Hypoxia-Inducible Factor-Proline Dioxygenases/antagonists & inhibitors , Hypoxia-Inducible Factor-Proline Dioxygenases/therapeutic use , Prolyl Hydroxylases , Prolyl-Hydroxylase Inhibitors/therapeutic use , Renal Insufficiency, Chronic/complications , Renal Insufficiency, Chronic/drug therapy , Renal Insufficiency, Chronic/veterinaryABSTRACT
BACKGROUND: Inhibition of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) stimulates erythropoiesis in rats, dogs, monkeys, and humans. HYPOTHESIS/OBJECTIVE: Determine if molidustat, a novel HIF-PH inhibitor, stimulates erythropoiesis in healthy cats. ANIMALS: Seventeen healthy adult laboratory cats. METHODS: Randomized, placebo-controlled study. Cats were treated PO once daily with suspensions of 0 (Group 1; n = 6), 5 (Group 2; n = 6), or 10 (Group 3; n = 5) mg/kg of molidustat. Effects on red blood cell parameters, reticulocyte indices and plasma erythropoietin (EPO) concentrations were evaluated. Molidustat treatment was stopped when hematocrit (HCT) exceeded 60%. RESULTS: Compared to placebo, a significant increase in mean HCT was evident starting on Day 14 (Group 2:54.4% vs 40.3%, P < .001, 95% confidence interval [CI] for the difference [8.95-19.28]; Group 3:61.2% vs 40.3%, P < .001, 95% CI [15.48-26.43]) and remained significantly higher for the entire treatment period. In molidustat-treated groups, HCT exceeded 60% on Day 21 (Group 2) and Day 14 (Group 3). Mean HCT in molidustat-treated cats returned to within the reference range (29%-45%) after Day 56 and was numerically comparable to placebo from Day 70 onwards. Red blood cell count and hemoglobin concentrations followed a similar pattern as HCT. Mean EPO concentrations significantly increased after molidustat administration on all assessment days. Molidustat treatments were well tolerated. CONCLUSIONS AND CLINICAL IMPORTANCE: Marked erythropoietic effects were identified after daily administration of molidustat to healthy cats and additional studies are warranted to evaluate the effects in anemic cats.
Subject(s)
Anemia , Cat Diseases , Animals , Cats , Anemia/veterinary , Cat Diseases/drug therapy , Cat Diseases/chemically induced , Erythropoiesis , Pyrazoles , Triazoles/pharmacologyABSTRACT
The efficacy of Felpreva® (Vetoquinol), a new spot-on application containing the novel acaricide and insecticide tigolaner in combination with emodepside and praziquantel, was evaluated in cats artificially infested with ear mites (Otodectes cynotis). A total of three pivotal dose confirmation studies were conducted, two of them designed as non-interference studies. Cats were artificially infested with O. cynotis mites and randomly allocated into groups of 8 cats based on pre-treatment mite counts. Cats were treated once on Day 0, either with Felpreva® (14.5 âmg/kg tigolaner, 3 âmg/kg emodepside and 12 âmg/kg praziquantel) or with placebo. Studies with a non-interference design included two additional groups of cats, treated with Profender® spot-on solution (Vetoquinol) (3 âmg/kg emodepside and 12 âmg/kg praziquantel) and tigolaner as a mono product (14.5 âmg/kg tigolaner). Efficacy was evaluated on Day 28/Day 30 based on total live mite counts after ear flushing. Efficacy was claimed when: (i) at least six control cats per group were adequately infested with mites; (ii) calculated efficacy was ≥ 90% based on geometric mean mite counts; and (iii) the difference in mite counts between Felpreva®-treated cats and control cats was statistically significant (P â≤ â0.05). In two of the three studies, Felpreva®-treated cats were mite-free (100% efficacy) on Day 28/Day 30 and almost full efficacy (99.6%) was seen in the third study. The difference in mite counts between Felpreva®-treated cats and control cats was significant (P â< â0.0001) in all three studies. All control cats were adequately infested in all three studies. The efficacy of Felpreva® against ear mite (Otodectes cynotis) infection in cats was confirmed.
ABSTRACT
The general WAAVP (World Association for the Advancement of Veterinary Parasitology) guideline on anthelmintic efficacy were prepared to assist researchers with the planning, conduct and interpretation of studies to assess the efficacy of anthelmintic drugs in food-producing and companion animals. General principles are outlined herein to assist in the preparation and execution of dosage determination, dosage confirmation and field studies, which are applicable to all animal host species. These general guidelines are complemented by revised species-specific guidelines, which provide more specific, updated and detailed guidance for each animal host species.
Subject(s)
Anthelmintics , Animals , Anthelmintics/therapeutic use , ParasitologyABSTRACT
Ancylostoma caninum is the most prevalent intestinal nematode of dogs, and has a zoonotic potential. Multiple-drug resistance (MDR) has been confirmed in a number of A. caninum isolates, including isolate Worthy 4.1F3P, against all anthelmintic drug classes approved for hookworm treatment in dogs in the United States (US). The cyclooctadepsipeptide emodepside is not registered to use in dogs in the US, but in a number of other countries/regions. The objective of this study was to evaluate the efficacy of emodepside + praziquantel, as well as three commercial products that are commonly used in the US for treatment of hookworms, against a suspected (subsequently confirmed) MDR A. caninum isolate Worthy 4.1F3P. 40 dogs infected on study day (SD) 0 with 300 third-stage larvae, were randomly allocated to one of five treatment groups with eight dogs each: pyrantel pamoate (Nemex®-2), fenbendazole (Panacur® C), milbemycin oxime (Interceptor®), emodepside + praziquantel tablets and non-treated control. Fecal egg counts (FEC) were performed on SDs 19, 20, 22, 27, 31 and 34. All treatments were administered as per label requirements on SD 24 to dogs in Groups 1 through 4. Two additional treatments were administered on SDs 25 and 26 to dogs in Group 2 as per label requirements. Dogs were necropsied on SD 34 and the digestive tract was removed/processed for worm recovery and enumeration. The geometric mean (GM) worm counts for the control group was 97.4, and for the pyrantel pamoate, fenbendazole, milbemycin oxime, and emodepside + praziquantel groups were 74.8, 72.0, 88.9, and 0.4, respectively. These yielded efficacies of 23.2%, 26.1%, and 8.8%, and 99.6%, respectively. These data support previous findings of the MDR status of Worthy 4.1F3P as treatments with pyrantel pamoate, fenbendazole and milbemycin oxime lacked efficacy. In sharp contrast, Worthy 4.1F3P was highly susceptible to treatment with emodepside + praziquantel.
Subject(s)
Ancylostomatoidea , Ancylostomiasis/veterinary , Anthelmintics/therapeutic use , Dog Diseases/parasitology , Ancylostomatoidea/isolation & purification , Ancylostomatoidea/pathogenicity , Ancylostomiasis/drug therapy , Animals , Anthelmintics/administration & dosage , Depsipeptides/administration & dosage , Depsipeptides/therapeutic use , Dog Diseases/drug therapy , Dogs , Drug Combinations , Drug Resistance, Multiple , Hookworm Infections/drug therapy , Hookworm Infections/veterinary , Intestines/parasitology , Macrolides/administration & dosage , Macrolides/therapeutic use , Praziquantel/administration & dosage , Praziquantel/therapeutic use , Pyrantel/administration & dosage , Pyrantel/therapeutic use , Treatment OutcomeABSTRACT
The capability of imidacloprid 10% + flumethrin 4.5% (Seresto®) collars to prevent transmission of Borrelia burgdorferi sensu lato (Bbsl) and Anaplasma phagocytophilum (Ap) by naturally infected ticks was evaluated in two studies with 44 dogs. In each study, one group served as non-treated control, whereas the other groups were treated with the Seresto® collar. All dogs were exposed to naturally Bbsl- and Ap-infected hard ticks (Ixodes ricinus, Ixodes scapularis). In study 1, tick infestation was performed on study day (SD) 63 (2 months post-treatment [p.t.]); in study 2, it was performed on SD 32 (one month p.t.) respectively SD 219 (seven months p.t.). In situ tick counts were performed 2 days after infestation. Tick counts and removals followed 6 (study 1) or 5 days (study 2) later. Blood sampling was performed for the detection of specific Bbsl and Ap antibodies and, in study 1, for the documentation of Ap DNA by PCR. Skin biopsies were examined for Bbsl by PCR and culture (only study 1). The efficacy against Ixodes spp. was 100% at all time points. In study 1, two of six non-treated dogs became infected with Bbsl, and four of six tested positive for Ap; none of the treated dogs tested positive for Bbsl or Ap. In study 2, ten of ten non-treated dogs became infected with Bbsl and Ap; none of the treated dogs tested positive for Bbsl or Ap; 100% acaricidal efficacy was shown in both studies. Transmission of Bbsl and Ap was successfully blocked for up to 7 months.
Subject(s)
Acaricides/therapeutic use , Disease Transmission, Infectious/veterinary , Dog Diseases/drug therapy , Ehrlichiosis/veterinary , Lyme Disease/veterinary , Tick Infestations/veterinary , Acaricides/administration & dosage , Anaplasma phagocytophilum/genetics , Anaplasma phagocytophilum/immunology , Anaplasma phagocytophilum/physiology , Animals , Antibodies, Bacterial/blood , Arachnid Vectors/microbiology , Borrelia burgdorferi/genetics , Borrelia burgdorferi/immunology , Borrelia burgdorferi/physiology , DNA, Bacterial/blood , Disease Transmission, Infectious/prevention & control , Dog Diseases/prevention & control , Dog Diseases/transmission , Dogs , Ehrlichiosis/prevention & control , Ehrlichiosis/transmission , Ixodes/microbiology , Lyme Disease/prevention & control , Lyme Disease/transmission , Neonicotinoids/administration & dosage , Nitro Compounds/administration & dosage , Pyrethrins/administration & dosage , Tick Infestations/drug therapy , Tick Infestations/microbiology , Tick Infestations/parasitology , Treatment OutcomeABSTRACT
BACKGROUND: The use of heat-treatment in canine and feline serum has been hypothesized to break the formation of antigen-antibody complexes, thereby freeing the heartworm antigen allowing for detection by commercially available heartworm antigen kits. While studies have analyzed the effect of heat-treating serum and plasma samples in the detection of heartworm antigen, these studies have not utilized necropsy verified results for validation. This study evaluated the use of heat-treating serum samples in experimentally infected dogs during adulticidal treatment in comparison with necropsy adult heartworm recovery. METHODS: As part of a primary study, a total of 16 dogs were experimentally infected with 16 sexually mature adult heartworms using surgical transplantation, allocating 8 dogs in both the control and treated group. Treated dogs received 10 months of topical administration of Advantage Multi® for Dogs (10% Imidacloprid + 2.5% Moxidectin) every 4 weeks and 30 days of 10 mg/kg doxycycline BID. Blood samples were collected from all study animals prior to surgical transplantation of adult heartworms, on study days 0, 1, 3, 7, 14, 21, 28, and every 4 weeks thereafter for the duration of this study. Concentration of heartworm antigen was tested using the DiroCHEK® heartworm antigen test kit using serum samples both pre- and post-heat-treatment. Serum samples were heat-treated at 103 °C in a dry heat block for 10 min and centrifuging at 1818× g for 20 min. RESULTS: There were a total of 4 instances (days 56, 140, 224 and 252) in 3 treated dogs in which a serum sample converted from negative for the detection of heartworm antigen prior to heat-treatment to positive for the detection of heartworm antigen post-heat-treatment. At necropsy, these dogs had no adult heartworms recovered and were all negative on antigen testing prior to and after heat treatment. There was 100% accuracy in the detection of either no infection, or 1-2 adult heartworm infections using the DiroCHEK in serum samples with and without heat-treatment at the time of necropsy. CONCLUSIONS: The DiroCHEK accurately diagnosed all dogs with live adults recovered at necropsy as heartworm antigen positive and all those dogs with no live adults recovered at necropsy as heartworm antigen negative without the use of heat-treatment for samples taken on the day of necropsy. Therefore, these results indicate that the use of heat-treating serum samples did not provide data of any additional value in the diagnosis of heartworm-positive dogs receiving treatment in this study. Additionally, these results may indicate that the conversion of serum samples from negative to positive for the presence of heartworm antigen with heat-treatment may not always accurately diagnose live adult heartworm infections since no adult heartworms were recovered at necropsy for those dogs in which a conversion event occurred. These conversion events may be detecting residual antigen leftover after all adult worms have died or may even be detecting off- target antigens, which have been denatured during heat-treatment. While a necropsy was not performed at the time of the conversion events, no live adult worms were recovered from any of the dogs in which a conversion event occurred earlier in treatment.
Subject(s)
Antigens, Helminth/blood , Dirofilaria immitis/immunology , Dirofilariasis/blood , Dirofilariasis/drug therapy , Doxycycline/administration & dosage , Macrolides/administration & dosage , Neonicotinoids/administration & dosage , Nitro Compounds/administration & dosage , Animals , Dirofilaria immitis/drug effects , Dirofilariasis/parasitology , Dog Diseases/blood , Dog Diseases/drug therapy , Dog Diseases/parasitology , Dogs , Drug Combinations , Drug Therapy, Combination , Female , Hot Temperature , MaleABSTRACT
BACKGROUND: Prior work has shown that the levels of moxidectin in dogs treated with Advantage Multi® for Dogs (Bayer Animal Health) remain at a high plasma concentration for the full month after application. The objective of this study was to demonstrate the efficacy of 10% imidacloprid + 2.5% moxidectin topical solution (Advantage Multi® for Dogs, also known as Advocate® for Dogs) for the prevention of heartworm infection and disease 30 days after just one application. METHODS: Two groups of eight dogs each were included. Dogs in Group 1 received the product (Advantage Multi® for Dogs) while those in Group 2 remained as nontreated controls. All dogs entering the study completed a physical examination including examination for Dirofilaria immitis antigen and circulating microfilariae. Dogs in Group 1 were treated on Study Day (SD) -30 as per the label recommendation. Thirty days later (SD 0) dogs in Groups 1 and 2 were subcutaneously infected in the inguinal region with approximately 50 infective third-stage D. immitis larvae ("Missouri" isolate). Blood was collected on SDs 120 and 147 for examination for D. immitis antigen and circulating microfilariae. On SD 148, all animals were euthanized and necropsied for recovery of adult heartworms. All procedures were performed in accordance with the VICH GL9 guidelines. RESULTS: Examination and worm counts made at necropsy showed no heartworms in the treated dogs (Group 1) compared with six of eight nontreated dogs (Group 2) with heartworms (range of 2-33). The treated dogs (Group 1) had significantly fewer heartworms (p < 0.05) compared with the nontreated controls (Group 2). CONCLUSION: The results demonstrated that 10% imidacloprid + 2.5% moxidectin topical solution (Advantage Multi® for Dogs) is efficacious for the prevention of heartworm infection and disease all month long with no observation of treatment-related adverse events.
Subject(s)
Dirofilaria immitis/drug effects , Dirofilariasis/prevention & control , Dog Diseases/prevention & control , Filaricides/administration & dosage , Macrolides/administration & dosage , Neonicotinoids/administration & dosage , Nitro Compounds/administration & dosage , Animals , Dirofilaria immitis/physiology , Dirofilariasis/parasitology , Dog Diseases/parasitology , Dogs , Female , Male , Time FactorsABSTRACT
BACKGROUND: Anecdotal reports support the position that the adulticidal heartworm treatment utilizing doxycycline and Advantage Multi®/Advocate® for Dogs (10% imidacloprid + 2.5% moxidectin) has successfully converted antigen-positive dogs to antigen-negative. To date, no controlled experimental studies have demonstrated the adulticidal efficacy of this treatment regimen. The aim of this study was to evaluate the parasitological and clinical efficacy of Advantage Multi® for Dogs (IMD + MOX) and doxycycline in heartworm-infected beagles. METHODS: This study utilized 16 dogs, 8 dogs in each of non-treated control and treated groups. A total of 16 adult Dirofilaria immitis (Missouri strain) were surgically transplanted into the jugular vein of each study dog. The treatment regimen of monthly IMD + MOX topically (per labeled dosage and administration) for 10 months and 10 mg/kg doxycycline BID orally for 30 days was initiated 30 days post-surgical transplant. Echocardiograms, radiographs, complete blood counts, clinical chemistry profiles, heartworm antigenemia and microfilaremia were evaluated every 4 weeks. Serum samples were assayed for heartworm antigen using the DiroCHEK® heartworm antigen test. The DiroCHEK® was performed according to the manufacturer's recommendations and read using a spectrophotometer at 490 nm. RESULTS: All dogs tested positive for the presence of heartworm antigen post-surgical transplant and prior to treatment. Heartworm antigen levels began declining in treated dogs 3 months post-treatment. Non-treated control dogs remained antigen-positive. No microfilariae were detected in treated dogs after 21 days post-treatment. At necropsy, adult heartworms were recovered from all non-treated control dogs with a range of 10-12 adult worms/dog for an average recovery of 10.6 adult heartworms/dog. In the IMD + MOX- and doxycycline-treated dogs, the range of adult heartworms recovered was 0-2 adult worms/dog, with five dogs having no adult heartworms present. The average adult heartworm recovery was 0.6/dog in the treated group. This treatment regimen demonstrated a 95.9% efficacy in eliminating adult heartworms (P < 0.0001). CONCLUSIONS: This study demonstrated that this treatment regimen successfully eliminated D. immitis microfilariae by 21 days post-treatment, reduced heartworm antigen concentration over time, and had a 95.9% efficacy in the elimination of mature adult heartworms. Based on this study, we conclude that this treatment regimen is a relatively quick, reliable and safe option to treat canine heartworm infection as compared to other treatment regimens involving macrocyclic lactones, when the approved drug melarsomine dihydrochloride is unavailable, contraindicated or declined by an owner unable to afford the more costly treatment or concerned about the potential side effects.
Subject(s)
Dirofilaria immitis/drug effects , Dirofilariasis/drug therapy , Dog Diseases/drug therapy , Doxycycline/therapeutic use , Filaricides/therapeutic use , Macrolides/therapeutic use , Neonicotinoids/therapeutic use , Nitro Compounds/therapeutic use , Administration, Topical , Animals , Antigens, Helminth/blood , Dirofilaria immitis/isolation & purification , Dirofilariasis/parasitology , Dog Diseases/parasitology , Dogs , Doxycycline/administration & dosage , Drug Therapy, Combination , Filaricides/administration & dosage , Macrolides/administration & dosage , Microfilariae/drug effects , Microfilariae/isolation & purification , Neonicotinoids/administration & dosage , Nitro Compounds/administration & dosage , Treatment OutcomeABSTRACT
BACKGROUND: This controlled laboratory study was designed to evaluate the efficacy of the 10 % imidacloprid/4.5 % flumethrin collar (Seresto®, Bayer Animal Health) against fleas (Ctenocephalides f. felis) on cats, when compared to fipronil (9.8 %w/w)/(s)-methoprene (11.8 % w/w) topical spot-on formulation (Frontline® Plus for Cats and Kittens, Merial). METHODS: Thirty cats were randomized into three groups of ten animals based on pre-treatment flea counts: Group 1: imidacloprid/flumethrin collar; Group 2: fipronil/(s)-methoprene topical spot-on and Group 3: non-treated controls. The imidacloprid/flumethrin collars were applied one time on Day 0, while the fipronil/(s)-methoprene spot-on was administered every 30 days from Day 0 through Day 210. Cats were infested with 100 fleas on study days 0, 7, 14, 29, 59, 89, 119, 149, 179, 209 and 239. All flea counts were conducted by combing to remove fleas on post-treatment days 2, 8, 15, 30, 60, 90, 120, 150, 180, 210 and 240. RESULTS: The efficacy of the imidacloprid/flumethrin collar ranged from 98.2 to 100 % for eight months. The efficacy of fipronil/(s)-methoprene spot-on ranged from 68.2 to 99.9 %. Efficacy was < 85 % for fipronil/(s)-methoprene on Days 90, 150 and 210. The flea counts in both treatment groups were significantly fewer than those in the non-treated control group at every post-treatment study day (P < 0.0001). In addition, there were significantly fewer fleas in the imidacloprid/flumethrin collar group when compared to the fipronil/(s)-methoprene group on Days 90, 150 and 210 (P < 0.0001). CONCLUSIONS: This study demonstrated that the imidacloprid/flumethrin collar (Seresto®, Bayer Animal Health) maintained excellent ( > 98.2 %) efficacy against fleas on cats for the entire 8 month study. Monthly applications of fipronil/(s)-methoprene (Frontline® Plus for Cats and Kittens, Merial) generally had high, but variable (68.2 to 99.9 %) efficacy over the course of the eight month study. Based on the very high residual efficacy achieved by the imidacloprid/flumethrin collar in this study, veterinarians should expect that this collar will control and eliminate existing flea infestations on cats and in their in-home premises as long as every flea infested host is treated.
Subject(s)
Cat Diseases/prevention & control , Ctenocephalides/drug effects , Flea Infestations/veterinary , Insecticides/administration & dosage , Animals , Cats , Drug Therapy, Combination , Female , Flea Infestations/prevention & control , Imidazoles/administration & dosage , Male , Methoprene/administration & dosage , Neonicotinoids , Nitro Compounds/administration & dosage , Pyrazoles/administration & dosage , Pyrethrins/administration & dosageABSTRACT
This randomised controlled laboratory study demonstrated the residual speed of efficacy of an imidacloprid/flumethrin collar (Seresto(®), Bayer) for the control of ticks (Dermacentor variabilis, Amblyomma americanum) at 6 and 12 hours postinfestation on dogs when compared to oral afoxolaner (NexGard(®), Merial). Dogs were randomised by pre-treatment tick counts: Group 1) imidacloprid 10 % (w/w) / flumethrin 4.5 % (w/w) collar, 2) afoxolaner chewable (dosage 3.1 - 6.2 mg/kg), and 3) non-treated controls. Ticks (50/species/dog) were infested on days 3, 14, 21, and 28; live (attached and non-attached) and dead attached ticks were counted 6 and 12 hours later. Efficacy against live D. variabilis at 6 hours for Group 1 was 95 - 100 % and for Group 2 was 38 - 48 %; efficacy at 12 hours for Group 1 was 97 - 100 % and for Group 2 was 27 - 59 %. Efficacy against A. americanum at 6 hours for Group 1 was 94 - 100 % and for Group 2 was < 0 - 38 %; efficacy at 12 hours for Group 1 was 98 - 100 % and for Group 2 was 1 - 40 %. Live and total (total live and dead attached) tick counts in Group 1 against both tick species were significantly lower (p ≤ 0.05) than Group 2 and 3 at all time points. The number of live or total ticks on Group 2 dogs was never significantly lower when compared to the respective number of ticks on Group 3 (controls). This study demonstrated that an imidacloprid/flumethrin collar was highly efficacious (94 - 100 %) at repelling and killing ticks on dogs at 6 and 12 hours post-infestation and was more efficacious than afoxolaner on all challenge days.
Subject(s)
Dog Diseases/parasitology , Imidazoles/therapeutic use , Isoxazoles/therapeutic use , Ixodidae/drug effects , Naphthalenes/therapeutic use , Nitro Compounds/therapeutic use , Pyrethrins/therapeutic use , Tick Infestations/veterinary , Administration, Oral , Administration, Topical , Animals , Dog Diseases/prevention & control , Dogs , Imidazoles/administration & dosage , Insecticides/administration & dosage , Insecticides/therapeutic use , Isoxazoles/administration & dosage , Naphthalenes/administration & dosage , Neonicotinoids , Nitro Compounds/administration & dosage , Pyrethrins/administration & dosage , Tick Infestations/prevention & controlABSTRACT
This controlled laboratory study demonstrated the residual speed of efficacy of an imidacloprid/flumethrin collar (Seresto(®), Bayer) for the control of ticks (Dermacentor variabilis, Amblyomma americanum) at 6 and 12 hours post-infestation on dogs when compared to oral fluralaner (Bravecto(®), Merck). Dogs were randomised by pre-treatment tick counts: Group 1) imidacloprid 10 % (w/w)/flumethrin 4.5 % (w/w) collar, 2) fluralaner (dosage 25.1 - 49.4 mg/kg), and 3) non-treated controls. Ticks (50/species/dog) were infested on days 3, 14, 21, 28, 42, and 56 followed by 50 D. variabilis on days 70 and 84. Live and dead attached ticks were counted 6 and 12 hours later. Efficacy against both species at 6 and 12 hours for Group 1 was 94 - 100 %. Efficacy for Group 2 against both species at 6 hours was 4 - 69 %; efficacy at 12 hours was 8 - 100 %. Live (attached and non-attached) tick counts at 6 hours in Group 1 were significantly lower (p ≤ 0.05) than counts in Group 2 and 3 on all days. At 12 hours, live counts were significantly lower (p ≤ 0.05) in Group 1 than Group 2 for D. variabilis from days 56 - 84 and for A. americanum from days 28 - 56. There were significantly fewer (p ≤ 0.05) total ticks (total live and dead attached) on dogs in Group 1 compared to Group 2 and 3 at all time points. This study demonstrated that an imidacloprid/flumethrin collar was highly efficacious (94 - 100 %) at repelling and killing ticks on dogs at 6 and 12 hours post-infestation and was more efficacious than fluralaner as early as 6 hours post-infestation on all challenge days.
Subject(s)
Dog Diseases/parasitology , Imidazoles/therapeutic use , Isoxazoles/therapeutic use , Ixodidae/drug effects , Nitro Compounds/therapeutic use , Pyrethrins/therapeutic use , Tick Infestations/veterinary , Administration, Oral , Administration, Topical , Animals , Dog Diseases/drug therapy , Dogs , Imidazoles/administration & dosage , Isoxazoles/administration & dosage , Male , Neonicotinoids , Nitro Compounds/administration & dosage , Pyrethrins/administration & dosage , Tick Infestations/drug therapyABSTRACT
This study examined the efficacy of 10 % imidacloprid + 2.5 % moxidectin topical solution (Advantage ® Multi, Advocate®, Bayer) for the treatment of circulating microfilariae from dogs naturally infected with Dirofilaria immitis. The study included two groups of 11 dogs each that consisted of two replicates. Replicate 1 contained 12 dogs (6 treated and 6 controls) and replicate 2 contained 10 dogs (5 treated and 5 controls). Six of the 10 dogs in replicate 2 were the controls from replicate 1. All dogs entering the study completed a physical examination including chest radiographs, blood collections for examination of Dirofilaria immitis circulating microfilariae, serum chemistry, complete blood counts and urinalysis. To qualify for the study each dog was required to have a geometric mean ≥ 300 microfilariae per ml of blood from 3 consecutive samples collected during the 8 day acclimation period and a heartworm disease classification of 1 or 2. Dogs were treated on study days 0 and 28. Post-treatment microfilarial counts were performed on study days 1, 2, 3, 7, 14, 21, 28, 29, 35, and 42. Percent microfilarial reduction was determined by comparing the geometric mean number of circulating microfilaria remaining in treated dogs with those remaining in the control dogs post-treatment. Seven days after the first treatment, the geometric mean microfilarial counts in treated dogs were reduced by > 99 % compared to the control dogs. Reduction remained at > 99 % through the end of the study at 42 days after the first treatment (14 days after the second treatment). The results of this study demonstrated that Advantage® Multi for dogs is efficacious for treatment of circulating D. immitis microfilariae in naturally infected heartworm-positive dogs with no treatment-related adverse events observed.
Subject(s)
Dirofilaria immitis/drug effects , Dirofilariasis/drug therapy , Dog Diseases/drug therapy , Imidazoles/therapeutic use , Macrolides/therapeutic use , Nitro Compounds/therapeutic use , Administration, Topical , Animals , Anthelmintics/administration & dosage , Anthelmintics/therapeutic use , Dog Diseases/parasitology , Dogs , Drug Combinations , Female , Imidazoles/administration & dosage , Insecticides/administration & dosage , Insecticides/therapeutic use , Macrolides/administration & dosage , Neonicotinoids , Nitro Compounds/administration & dosageABSTRACT
A controlled laboratory study was conducted to establish the safety and efficacy of 10% imidacloprid+2.5% moxidectin topical solution (Advantage Multi® for Dogs, Bayer HealthCare, Shawnee, KS) for the treatment of circulating Dirofilaria immitis microfilariae in dogs. Twenty beagles were experimentally infected with D. immitis via surgical implantation of 10 pairs of adult worms (Pepper strain, TRS Labs) from donor dogs on Day -82. Between Days -7 and -1, physical examinations were performed, chest radiographs were taken, and blood and urine samples were collected for microfilariae counts, serum chemistry, complete blood counts, and urinalysis. Each dog was required to have a mean pretreatment count of at least 300 mf/ml of blood. On Day -1, all 20 dogs were randomized by mean pretreatment microfilarial counts to two study groups (10 animals/group). Animals in Group 1 were treated on Days 0 and 28 with 10% imidacloprid+2.5% moxidectin topical solution at the minimum label dose of 0.1 ml/kg. Group 2 animals served as negative controls and were treated on Days 0 and 28 with mineral oil at an equivalent volume as for the study solution. All dogs were observed hourly for 8h after treatment, again at 12h, and then once daily on all other study days. Blood samples for microfilarial counts were collected daily for 3 days after treatment and then weekly for 6 weeks. The percentage reduction in microfilariae was determined by comparing the geometric mean number of circulating microfilariae remaining in Group 1 dogs with the mean counts remaining in control dogs. Group 1 mean microfilarial counts were reduced 93.1% three days following the first treatment and by >99% on Days 14 through 42. Group 1 had significantly fewer (p<0.05) microfilariae compared with Group 2 counts on Days 28 and 42. In addition, log-transformed geometric mean microfilarial counts were significantly different between the two groups (p<0.05) using separate repeated measures analysis of covariance for Days 2, 3, 7, 14, 21, 28, 35, and 42. No adverse events related to treatment were reported during the study. The results of this study demonstrate that 10% imidacloprid+2.5% moxidectin topical solution is efficacious for treatment of circulating D. immitis microfilariae in heartworm-positive dogs with no treatment-related adverse events observed.
Subject(s)
Dirofilariasis/drug therapy , Dog Diseases/drug therapy , Imidazoles/administration & dosage , Macrolides/administration & dosage , Nitro Compounds/administration & dosage , Animals , Dirofilaria immitis/drug effects , Dogs , Drug Therapy, Combination/veterinary , Female , Filaricides/administration & dosage , Filaricides/pharmacology , Imidazoles/pharmacology , Macrolides/pharmacology , Male , Microfilariae/drug effects , Neonicotinoids , Nitro Compounds/pharmacology , Random Allocation , Treatment OutcomeABSTRACT
The efficacy of emodepside plus toltrazuril (Procox® oral suspension for dogs) against different species of gastrointestinal nematodes (Toxocara canis, Ancylostoma caninum, Uncinaria stenocephala) was evaluated in nine randomised,blinded and placebo-controlled laboratory studies in naturally or experimentally infected dogs. The product was used at the proposed minimum dose of 0.45 mg emodepside and 9 mg toltrazuril per kg body weight. Efficacy was calculated based on worm counts after necropsy. Worm burdens in the control dogs ranged between 0 and 409 worms of the respective stage for T. canis and between 4 and 655 worms for hookworms. The studies demonstrated 100 % efficacy of emodepside/toltrazuril suspension against mature adult, ≥ 94.7 %efficacy against immature adult and 99.3 % efficacy against the L4 larval stage of T. canis. The efficacy against mature adult A. caninum was ≥ 99.5 % and the efficacy against mature adult U. stenocephala was 100 %. All differences between treatment and control groups were statistically significant and no gender effect was found. It can be concluded that the emodepside/toltrazuril suspension represents a safe and highly effective product in dogs with nematode (T. canis, hookworms) infection.
Subject(s)
Ancylostoma/drug effects , Ancylostomatoidea/drug effects , Depsipeptides/therapeutic use , Dog Diseases/drug therapy , Hookworm Infections/veterinary , Toxocara canis/drug effects , Toxocariasis/drug therapy , Triazines/therapeutic use , Administration, Oral , Ancylostoma/pathogenicity , Ancylostomatoidea/pathogenicity , Animals , Anthelmintics/administration & dosage , Anthelmintics/therapeutic use , Depsipeptides/administration & dosage , Dog Diseases/parasitology , Dogs , Double-Blind Method , Drug Combinations , Drug Evaluation , Female , Hookworm Infections/drug therapy , Hookworm Infections/parasitology , Larva/drug effects , Larva/parasitology , Male , Parasite Egg Count/veterinary , Toxocara canis/pathogenicity , Toxocariasis/parasitology , Triazines/administration & dosageABSTRACT
Three randomised, blinded and placebo-controlled laboratory studies were conducted to evaluate the efficacy of emodepside plus toltrazuril suspension (Procox(®) suspension for dogs) against Isospora canis and Isospora ohioensis-complex. Unweaned puppies were experimentally infected with sporulated oocysts of I. canis and/or I. ohioensis-complex. In each study, one group was treated during prepatency (2 or 4 days post infection) while dogs in the second group were treated individually after the onset of oocyst excretion of the respective coccidia species. The dogs were treated with the minimum therapeutic dose of 0.45 mg emodepside and 9 mg toltrazuril per kg body weight. Daily faecal oocyst counts from both groups were compared to placebotreated control groups to determine efficacy.Dogs treated during prepatent I. canis or I. ohioensis-complex infection showed significantly lower oocyst counts for up to 12 days compared to the control group. Oocyst counts were reduced by 90.2 - 100 % while the control groups continued to exhibit an adequate infection, except for one study where efficacy against prepatent I. canis infection faded 13 days after treatment. Following treatment of patent I. canis or I. ohioensis-complex infections, significantly lowered oocyst counts were observed for up to 9 days compared to the control group. Faecal oocyst counts were reduced by 91.5 - 100 %. In all three studies the number of days with diarrhoea was significantly lower when dogs were treated during prepatent Isospora spp. infection compared to the control groups. No adverse drug reactions were observed during the studies. In conclusion, the studies demonstrated that emodepside plus toltrazuril suspension is an efficient coccidiocide for dogs.
Subject(s)
Coccidiostats/therapeutic use , Depsipeptides/therapeutic use , Dog Diseases/drug therapy , Isospora/drug effects , Isosporiasis/drug therapy , Triazines/therapeutic use , Animals , Depsipeptides/administration & dosage , Diarrhea/parasitology , Dog Diseases/parasitology , Dogs , Double-Blind Method , Drug Combinations , Drug Evaluation , Isospora/pathogenicity , Isosporiasis/parasitology , Parasite Egg Count/veterinary , Triazines/administration & dosageABSTRACT
Crenosoma vulpis is a metastrongylid lungworm of canids causing chronic respiratory disease in dogs in parts of North America and Europe. The objective of this study was to determine the efficacy of imidacloprid 10% + moxidectin 2.5% (Advantage Multi/Advocate Topical Solution) against C. vulpis infection in experimentally infected dogs. Eighteen beagles (9 M, 9 F) were each given 100 infective third-stage larvae of C. vulpis. The 16 dogs (8 M, 8 F) with the highest faecal larval counts were stratified by gender and larval counts and randomly assigned to a treatment group. Group 1 received placebo only; group 2 was given a single topical treatment of Advantage Multi/Advocate (10 mg/kg imidacloprid/2.5 mg/kg moxidectin) at 4 weeks PI. Dogs were euthanised at 8 weeks PI and the lungs were removed and examined for the presence of adult worms by lung flush. The mean (geometric) number for adult C. vulpis recovered in untreated dogs was 70.0 (range 58 to 87) compared with 0.0 in animals treated with Advantage Multi/Advocate. The resulting efficacy against C. vulpis was 100%. The number of C. vulpis was significantly lower for treated dogs than the burden shown in the untreated group (p = 0.003).